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A B S T R A C T
The aim of the study was to assess a relationship between circulating platelet aggre-
gates (CPA) and progression of visual field loss in primary open-angle glaucoma pa-
tients. CPA was determined in 27 patients with open-angle glaucoma with nonprogres-
sive visual field loss and 15 patients with open-angle glaucoma and progression of vi-
sual field loss. Intraocular pressure (IOP) under topical therapy was <18 mmHg in all
patients. CPA in glaucoma patients with progression of visual field loss was not signifi-
cantly higher than those without visual field progression (p=0.59). In conclusion, our
study shows that increased platelet aggregability is not solely responsible for progres-
sion of visual field loss in glaucoma patients, and indicates the role of IOP in the patho-
genesis of visual field loss.
Introduction
Glaucoma is multifactorial syndrome
of progressive optic neuropathy charac-
terized by an unphysiological large
cup/disc ratio with reduced retinal sensi-
tivity, visual field defects and additional
psychophysical alterations1. In addition
to intraocular pressure (IOP) which is an
established risk factor, many other risk
factors have been described2. Both IOP
and vascular factors appear to play an
important role in the pathogenesis of
glaucomatous optic neuropathy3. Rheo-
logical factors remain controversial. An
increase in platelet adhesiveness has
been found in some studies, while others
have found differences in fibrinolysis4–7.
Hoyng et al found an age dependent asso-
ciation between spontaneous platelet ag-
gregation (SPA) and visual field deterio-
ration in glaucoma patients4,7,8. Platelet
activation in circulation can be followed
by measurement of circulating platelet
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aggregates (CPA) in venous blood9. It was
shown that the level of CPA was higher in
glaucoma patients than in normal con-
trol5.
In this study we tried to evaluate a hy-
pothesis that a higher level of CPA in
some glaucoma patients with progression
of visual field defects and IOP in statisti-
cally normal range could be responsible
for progression of visual field loss.
Patients and Methods
In controlled clinical study the pa-
tients were divided into two groups: ex-
perimental and control group. The exper-
imental group consisted of 27 primary
(high-pressure) open angle glaucoma pa-
tients. Patients were required to have a
diagnosis of open-angle glaucoma, includ-
ing IOP under topical therapy <18 mmHg,
papillary excavation (C/D>0.5), non pro-
gressive visual field loss demonstrated by
Goldmann perimetry and no other ocular
abnormality that would affect the visual
field. A control group consisted of 15 pri-
mary (high-pressure) open-angle glauco-
ma patients with papillary excavation
(C/D>0.5), IOP under topical therapy <18
mmHg and progressive visual field loss. A
progressive visual field loss was consid-
ered progressive if the following changes
developed within a period of less than six
months: enlargement of the paracentral
and nasal scotoma by >5° or >10° in diame-
ter, occurrence of new scotomatous de-
fects and progression of relative into ab-
solute scotoma.
Patients were excluded if they had
any disease or were taking medications
known to modify the aggregability of the
blood, or had arterial hypertension or hy-
potension, diabetes mellitus, and cardio-
vascular disease or smoking.
The ratio of CPA was investigated ac-
cording to the platelet function system
described by Wu and Hoak and modified
by Kiesewetter et al9,10.
Briefly, the test for circulating aggre-
gates was based on the effect of ethylen-
diaminetetraacetic acid (EDTA) and for-
malin (a 40% solution of gaseous formal-
dehyde) on platelet aggregates occurring
in vivo or resulting from blood sampling.
These aggregates were broken up by
EDTA, but immediately fixed with EDTA
+ formalin. Blood samples were obtained
using a two-syringe technique. Each 0.5
ml blood sample was added to 2 ml buf-
fered EDTA or to 2 ml buffered EDTA +
formalin. The blood picture was deter-
mined in each sample. The platelets were
counted in an electronic particle counter
(Tehnicon instruments, New York, USA).
Blood samples were taken at 9 a.m. to
avoid diurnal variations11.
The results were expressed as a ratio
of the platelet count in the buffered
EDTA solution divided by the platelet
count in the buffered EDTA + formalin so-
lution. The calculated ratio is the inverse
of that described by Wu and Hoak9.
The quotient becomes larger with in-
creased CPA. CPA values greater than
1.05 should arouse suspicion, while val-
ues over 1.2 are pathologic10.
Statistical analysis was performed us-
ing Statistica for Windows (Stat Soft Inc,
USA, Version 6.0). All data were analyzed
by a descriptive analysis. Comparisons
between the platelet aggregate ratio of the
two groups and comparisons in platelet
aggregability according to sex were made
using the non-parametric Mann-Whitney
U test. A Chi-square test and Student's
t-test were used to compare patients’ data
such as sex and age. Findings with an er-
ror probability value of <0.05 were con-
sidered to be statistically significant.
Results
The demographic data of all patients
are shown in Table 1. The results of plate-
let aggregates studies in glaucoma pati-
ents are given in Table 2.
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Using the Mann-Whitney U-test we
did not find a significant difference be-
tween the groups (z=0.52; p=0.59).
No significant gender-based differences
in platelet aggregability were found in
glaucoma patients with non progressive
visual field loss (z=0.73; p=0.46) or those
with progressive visual field loss (z=0.81;
p=0.41).
Discussion
Despite the achieved IOP <18 mmHg
in primary (high pressure) open-angle
glaucoma, progression of visual field loss
and optic nerve cupping continues in
many subjects12,13. Vascular factors have
been implicated in the development of
glaucomatous damage1. The mechanism
of their involvement, either as part of a
generalized vascular disorder or as a pu-
rely localized disturbance are still un-
clear. Rheological factors remain contro-
versial4,5,7,8,13,14. Hoyng et al. found that
glaucoma patients over 70 years old have
a high incidence of SPA. It was specu-
lated that an intravascular condition
such as SPA plays a pathogenic role in
some glaucoma patients7. A relationship
between SPA, visual field damage and
disc hemorrhages was observed by Hoyng
et al4,8. To what extent platelet hyperac-
tivity is involved in the pathogenesis of
glaucoma is not well understood. Recent
studies point to activation of the coagula-
tion cascade and fibrinolysis in glauco-
ma15. The measurement of CPA is a sim-
ple method for clinical evaluation of pla-
telet hyperfunction16. According to Iwase
et al. SPA is more sensitive than agonist
induced platelet aggregation in diabe-
tes16. We did not find a difference in pla-
telet aggregability according to sex, that
is, in accordance with observations of Ab-
bate et al17. Hoyng et al. found that in
glaucoma patients with progression of vi-
sual field loss has higher prevalence of
SPA than in glaucoma patients without
deterioration of visual field decay4,8. The
result of our study showed that the level
of CPA are not significantly increased in
glaucoma patients with progression of vi-
sual field loss compared in those without
progression of visual field loss. Our re-
sults could not be compared with the stu-
dies of Hyong et al. because the mean age
of glaucoma patients in their studies was
higher than in our study and the platelet
aggregation in vitro (according to Born)
was performed4,8).
Although there was no statistical dif-
ference in CPA values between the two
groups, the CPA values are pathologic
and the CPA value of the glaucoma pa-
tients with progression of visual field was
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TABLE 2




Experimental (N=27) 1.27 0.47*
Control (N=15) 1.41 0.65
*Mann-Whitney U-test; z = 0.52, p = 0.59
TABLE 1
DEMOGRAPHIC DATA OF ALL PATIENTS
Experimental Control p
N 27 15
Sex (M/F) 12/15 8/7 0.58b
Mean age (X SD) 58.1 4.4 60.6 4.2 0.08a
IOP (X SD) 16.0 2.1 16.9 1.1 0.02a
a Student’s t-test; b  2 test
higher than those without progression.
Further controlled studies may be requi-
red to clarify this. Recently, Matsumoto
et al. found that increased platelet aggre-
gation as defined by adenosine diphos-
phate or collagen induced abnormal sec-
ondary aggregation in vitro is frequently
associated with glaucoma18.
Our study showed that visual fields
continued to progression although the
level of IOP was <17 mmHg.A recent
study by the Advanced Glaucoma Inter-
vention Study group showed that visual
progression loss can be practically halted
if the IOP is lowered below 12 mmHg19.
In conclusion, our study shows that
increased platelet aggregability is not
solely responsible for the progression of
visual field loss in glaucoma patients and
indicates the role of IOP in the pathoge-
nesis of the visual field loss.
It might be necessary to conduct more
clinical trials in order to provide more in-
formation about the role of platelet aggre-
gability in glaucoma, and identify those
risk factors, which are potentially treat-
able in order to prevent the progression of
glaucomatous damage.
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CIRKULIRAJU]I AGREGATNI KOMPLEKSI I PROGRESIJA GUBITKA
VIDNOG POLJA KOD GLAUKOMA
S A @ E T A K
Cilj rada je utvrditi vezu izme|u cirkuliraju}ih trombocitnih agregata (CTA) i pro-
gresije gubitka vidnog polja kod primarnog glaukoma otvorenog kuta. CTA su ispitiva-
ni kod 27 glaukomskih bolesnika otvorenog kuta sa stabilnim vidnim poljem, kao i kod
15 bolesnika sa glaukomom otvorenog kuta s progresijom gubitka vidnog polja. Intra-
okularni tlak (IOT) kod svih bolesnika bio je manji od 18 mmHg, uz lokalnu terapiju.
CTA kod bolesnika sa progresijom gubitka vidnog polja nisu bili zna~ajno ve}i od onih
sa stabilnim vidnim poljem (p = 0,59). U zaklju~ku, na{a studija pokazuje da agregabil-
nost trombocita nije isklju~ivo odgovorna za progresiju gubitka vidnog polja kod glau-
komskih bolesnika i ukazuje na ulogu IOT-a u patogenezi gubitka vidnog polja.
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